Search Within

Dana Elizabeth Rathkopf

  1. "Journal of Clinical Oncology"
Formats
  1. Meeting Abstract (112)
  2. Journal Article (10)
Groups
  1. Department of Medicine (122)
  2. Genitourinary Oncology Service (122)
  3. Solid Tumor Oncology Division (122)
  4. Hematologic Malignancies, Division of (37)
  5. GSK Faculty (25)
  6. Department of Pathology and Laboratory Medicine (19)

More Groups

People
  1. Howard Scher (64)
  2. Michael Morris (41)
  3. Susan Slovin (36)
  4. Daniel Danila (26)
  5. Steven Larson (15)
  6. Karen Autio (14)

More People

Years
  1. 2025 (3)
  2. 2024 (6)
  3. 2023 (8)
  4. 2022 (4)
  5. 2021 (7)
  6. 2020 (4)

More Years

Publications
  1. Journal of Clinical Oncology (122)
Publishers
  1. American Society of Clinical Oncology (122)

Results (122)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Blood biomarkers and association with clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC): Prespecified longitudinal analysis from the ACIS study of apalutamide (APA) or placebo combined with abiraterone acetate plus prednisone (AAP)
    Meeting Abstract

    Efstathiou, E.; Attard, G.; Lucas, J.; Thomas, S.; Gormley, M.; Aguilar-Bonavides, C.; Flaig, T. W.; Franke, F.; Goodman, O. B.; Oudard, S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Analysis of two poor prognosis subgroups in ACIS evaluating apalutamide + abiraterone acetate plus prednisone (APA + AAP) versus placebo (PBO) + AAP in metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Saad, F.; Efstathiou, E.; Attard, G.; Flaig, T. W.; Franke, F.; Goodman, O.; Oudard, S.; Steuber, T.; Suzuki, H.; Pieczonka, C. M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • First-in-human study of TAS3681, an oral androgen receptor (AR) antagonist with AR and AR splice variant (AR-SV) downregulation activity, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) refractory to abiraterone (ABI) and/or enzalutamide (ENZ) and chemotherapy (CT)
    Meeting Abstract

    De Bono, J. S.; Cook, N.; Yu, E. Y.; Lara, P. N.; Wang, J. S.; Yamasaki, Y.; Yamamiya, I.; Gao, P.; Calleja, E. M.; Rathkopf, D. E.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Interim results of AASUR: A single arm, multi-center phase 2 trial of apalutamide (A) + abiraterone acetate + prednisone (AA plus P) + leuprolide with stereotactic ultra-hypofractionated radiation (UHRT) in very high risk (VHR), node negative (N0) prostate cancer (PCa)
    Meeting Abstract

    McBride, S. M.; Spratt, D. E.; Kollmeier, M.; Abida, W.; Xiao, H.; Slovin, S. F.; Paller, C. J.; Deville, C.; Den, R. B.; Hearn, J. W. D.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Prospective evaluation of clinical outcomes using a multiplex liquid biopsy targeting diverse resistance mechanisms in metastatic prostate cancer
    Journal Article

    Sperger, J. M.; Emamekhoo, H.; McKay, R. R.; Stahlfeld, C. N.; Singh, A.; Chen, X. E.; Kwak, L.; Gilsdorf, C. S.; Wolfe, S. K.; Wei, X. X.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • AMPLITUDE: A study of niraparib in combination with abiraterone acetate plus prednisone (AAP) versus AAP for the treatment of patients with deleterious germline or somatic homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC)
    Meeting Abstract

    Rathkopf, D. E.; Chi, K. N.; Olmos, D.; Cheng, H. H.; Agarwal, N.; Graff, J. N.; Sandhu, S. K.; Hayreh, V.; Lopez-Gitlitz, A.; Francis, P. S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Final results from ACIS, a randomized, placebo (PBO)-controlled double-blind phase 3 study of apalutamide (APA) and abiraterone acetate plus prednisone (AAP) versus AAP in patients (pts) with chemo-naive metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Rathkopf, D. E.; Efstathiou, E.; Attard, G.; Flaig, T. W.; Franke, F. A.; Goodman, O. B.; Oudard, S.; Steuber, T.; Suzuki, H.; Wu, D.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Evaluating the role of stereotactic body radiation therapy with respect to androgen receptor signaling inhibitors for metastatic prostate cancer
    Meeting Abstract

    Brennan, V.; Spektor, A.; Sweeney, C.; Choudhury, A. D.; Rathkopf, D. E.; Pomerantz, M.; Hertan, L. M.; Martin, N. E.; Nguyen, P. L.; Balboni, T. A.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Changes in Ki-67 and cleaved caspase-3 (CC3) with short term androgen deprivation therapy (ADT) prior to prostatectomy as part of a trial in intermediate and high-risk prostate cancer (PC)
    Meeting Abstract

    Vargas Pivato de Almeida, D.; Chen, Y. B.; Autio, K. A.; Carver, B. S.; Slovin, S. F.; Danila, D. C.; Scher, H. I.; Touijer, K. A.; Rathkopf, D. E.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (MAGNITUDE)
    Meeting Abstract

    Chi, K. N.; Rathkopf, D. E.; Attard, G.; Smith, M. R.; Efstathiou, E.; Olmos, D.; Small, E. J.; Lee, J. Y.; Ricci, D. S.; Simon, J. S.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save